Cargando…
Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
PURPOSE: The purpose of this study was to evaluate the long-term safety, anatomical, and visual outcomes following intravitreal bevacizumab (Avastin; Genentech) on macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: A prospective, interventional case series study was condu...
Autores principales: | Thapa, Raba, Maharjan, Nhukesh, Paudyal, Govinda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413343/ https://www.ncbi.nlm.nih.gov/pubmed/22888203 http://dx.doi.org/10.2147/OPTH.S30555 |
Ejemplares similares
-
Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
por: Demir, Mehmet, et al.
Publicado: (2011) -
Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Kim, Jin Young, et al.
Publicado: (2009) -
The comparison of intravitreal triamcinolone and bevacizumab in patients with macular edema secondary to branch retinal vein occlusion
por: Gokce, Gokcen, et al.
Publicado: (2014) -
Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Wang, Jia-Kang, et al.
Publicado: (2016) -
Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Ahn, Seong Joon, et al.
Publicado: (2013)